How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.
Pharma & Biotech
Pharma & Biotech
Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to